RecruitingPhase 1Phase 2NCT07700160

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

Sponsor

VelaVigo Bio Inc

Enrollment

230 participants

Start Date

Jul 30, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VBC108 for people with advanced solid tumors. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVBC108

VBC108

Locations(12)

City of Hope Medical Center

Duarte, California, United States

START Midwest, LLC

Grand Rapids, Michigan, United States

Laura and Issac Perlmutter Cancer Center

New York, New York, United States

Next Oncology - Oncology

San Antonio, Texas, United States

NEXT Oncology Virginia

Fairfax, Virginia, United States

GenesisCare North Shore

St Leonards, New South Wales, Australia

One Clinical Research

Perth, Western Australia, Australia

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Beijing GoBroad Hospital

Beijing, Beijing Municipality, China

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07700160

Related Trials

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT07435038

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT0600424538 locations

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT073495379 locations

A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

NCT066052221 location

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT067990656 locations